June 2017
Volume 58, Issue 8
ARVO Annual Meeting Abstract  |   June 2017
Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.
Author Affiliations & Notes
  • Rebecca Kaye
    Ophthalmology, Southampton General Hospital, Southampton, United Kingdom
  • Andrew J Lotery
    Ophthalmology, Southampton General Hospital, Southampton, United Kingdom
  • Footnotes
    Commercial Relationships   Rebecca Kaye, None; Andrew Lotery, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 229. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rebecca Kaye, Andrew J Lotery; Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):229.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Sorsby fundus dystrophy is a rare autosomal dominant disease characterised by bilateral loss of central vision in the third-fifth decade attributed to choroidal neovascularisation. To date there is no definitive treatment, however, several case reports have documented the use of anti-vascular endothelial growth factor antibodies (anti-VEGF) to maintain vision. We describe the first long-term study of the use of anti-VEGF therapy, specifically bevacizumab in Sorsby fundus dystrophy.

Methods : A 5-year retrospective case series was undertaken. All patients with a mutation in tissue inhibitor of metalloproteinases-3 (TIMP3) for Sorsby fundus dystrophy treated with intra-vitreal bevacizumab injections and at least five years follow-up were included. Consent for therapy was gained from all participants. Primary outcomes were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) , presence of sub-retinal fluid and macular scar on OCT. Data was analysed using a linear general model in SPSS.

Results : Nine patients were recruited and five included in the study. The mean and median number of intra-vitreal bevacizumab injections per eye was 16 and 6. At presentation BCVA was 0.1 +/-0.1 LogMAR units (mean+/- standard deviation) and CMT 242 +/-36μm. At five years BCVA was 0.65+/-0.42 LogMAR units and CMT 205+/-27μm. The association between change in CMT and intra-vitreal bevacizumab injections was significant (p=0.028). Persistence of sub-retinal fluid was significantly associated with a reduction in BCVA (p=0.001). Use of bevacizumab therapy in the presence of sub-retinal fluid was significantly associated with improvement in VA (p=0.027). There was, however, a linear decrease in VA of approximately 0.1 LogMAR units per year until scar formation.

Conclusions : In patients with Sorsby fundus dystrophy use of bevacizumab appears to provide a temporary stabilisation in BCVA through reduction in sub-retinal fluid. Its use, however, is of limited value once macular scar formation has occurred. These results suggest that an as required approach to therapy may need to be changed to a treat and extend approach, similar to changes in care pathways now being implemented for choroidal neovascularization associated with age related macular degeneration.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.